Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D plus T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

被引：2

作者：

Flaherty, Keith

Daud, Adil

Weber, Jeffrey S.

Sosman, Jeffrey Alan

Kim, Kevin

Gonzalez, Rene

Hamid, Omid

Infante, Jeffrey R.

Cebon, Jonathan S.

Schuchter, Lynn Mara

Long, Georgina V.

Algazi, Alain Patrick

Kudchadkar, Ragini Reiney

Puzanov, Igor

Lawrence, Donald P.

Kline, Amy S.

Cunningham, Elizabeth Ann

Sun, Peng

Patel, Kiran

Kefford, Richard

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33682 USA

[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] UCHSC, Anschultz Canc Pavil, Aurora, CO USA

[7] Angeles Clin & Res Inst, Los Angeles, CA USA

[8] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[9] Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia

[10] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[11] Melanoma Inst Australia, Sydney, NSW, Australia

[12] Univ Sydney, Sydney, NSW 2006, Australia

[13] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[14] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[15] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Thomas Jefferson Univ, Collegeville, PA USA

[18] Westmead Hosp, Westmead, NSW 2145, Australia

[19] Univ Sydney, Melanoma Inst Australia, Westmead, NSW 2145, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.9010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9010

引用

页数：2